Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — SPAC Merger (May 2021)
20 slides from Jasper Therapeutics's SPAC merger presentation, May 7, 2021
Slide 1: Enabling Cures with Hematopoietic Stem Cell Transplants
Enabling Cures with Hematopoietic Stem Cell Transplants May 2021
Slide 2: Safe Harbor Statement
© 2021 Jasper Therapeutics, Inc. Safe Harbor Statement 2 About this Presentation This investor presentation (this “Presentation”) is for informational purposes only to assist interested parties in making th eir own evaluation with respect to the proposed business combination (the “Proposed Business
Slide 3: Jasper Therapeutics Highlights: Science Based on Hematopoietic Stem Cells and Their Biology
© 2021 Jasper Therapeutics, Inc. Jasper Therapeutics Highlights: Science Based on Hematopoietic Stem Cells and Their Biology 3 • Platform of cell engineered programs to increase the cure rate of allogeneic and gene therapy grafts as well as improve their safety • Multiple in - vitro and in - vivo pr
Slide 4: Management Team and Scientific Advisory Board
© 2021 Jasper Therapeutics, Inc. Management Team and Scientific Advisory Board: Drug Development & Company Building Track Record and Experts in the Field 4 MANAGEMENT William Lis , Executive Chair & CEO Kevin N. Heller , Executive Vice President, Research and Development Jeet Mahal , Chief Financial
Slide 5: Unmet Medical Need: Hematopoietic Stem Cell Transplants Remain Underutilized
© 2021 Jasper Therapeutics, Inc. Unmet Medical Need: Hematopoietic Stem Cell Transplants (HSCT) Most Powerful Form of Disease Cure, Yet Remain Underutilized 5 Jasper Therapeutics could exponentially expand the eligible patient population for both allogeneic and autologous gene edited hematopoietic s
Slide 6: Jasper's Science is Focused on the Stem Cell, Targeting Stem Cell Factor Receptor
© 2021 Jasper Therapeutics, Inc. Jasper’s Science is Focused on the Stem Cell, Targeting Stem Cell Factor Receptor & Expanding to Novel Cell Engineering 6 • Stem Cell Factor (SCF) / Stem Cell Factor Receptor (CD117) interaction required for stem cell survival • JSP191 blocks SCF signaling leading to
Slide 7: Jasper's Expanding Pipeline
© 2021 Jasper Therapeutics, Inc. Jasper’s Expanding Pipeline 7 PROGRAM RESEARCH IND - ENABLING CLINICAL COMMERCIAL JSP191 CONDITIONING AML/ MDS SCID Autoimmune (Lupus, MS, Scleroderma) Fanconi’s Anemia Sickle Cell Disease Gene Therapy (X - SCID) Jasper eHSC GRAFTS Thalassemias Sickle Cell Disease Au
Slide 8: Unique and Differentiated JSP191 Properties Compared to All Other CD117 Antibodies
© 2021 Jasper Therapeutics, Inc. Unique and Differentiated JSP191 Properties Compared to All Other CD117 Antibodies Only anti - CD117 antibody that inhibits stem cell factor survival signal resulting in targeted depletion • Only JSP191 shows in - vivo single agent depletion • JSP191 SCF signal inhib
Slide 9: JSP191's First Clinical POC in Ultra Orphan Indication, SCID
© 2021 Jasper Therapeutics, Inc. JSP191’s First Clinical POC in Ultra Orphan Indication, Severe Combined Immunodeficiency (SCID) SCID is a lethal genetic immune disorder. HCT is the only proven cure, without it most infants die before the age of two year s. 9 Jasper SCID Clinical Trial Single Arm Tr
Slide 10: JSP191 Conditioning in SCID HCT Demonstrates Durable Naive T-cell Production
© 2021 Jasper Therapeutics, Inc. JSP191 Conditioning in SCID HCT Demonstrates Durable Naive T - cell Production and Immune System Reconstitution 10 Naïve CD4 T cell production post - cell infusion A. No Conditioning (Matched Cohort Patient) B. JSP191 Conditioning *85 /µL *Expected Level for Clinical
Slide 11: JSP191 Conditioning Leads to Successful Transplant and MRD Negative Status in AML & MDS
© 2021 Jasper Therapeutics, Inc. JSP191 Conditioning Leads to Successful Transplant and Conversion to MRD Negative Status/ MRD Reduction in First AML & MDS Patients 11 No treatment related SAEs MRD Positive AML/MDS Patients Not Eligible for Standard Myeloablative Regimens (HCT - Cl >2) MRD Status at
Slide 12: Jasper Engineered Hematopoietic Stem Cells (eHSC) Platform
© 2021 Jasper Therapeutics, Inc. Jasper Engineered Hematopoietic Stem Cells ( eHSC ) Platform: Unlocking the Potential of Stem Cells Jasper eHSCs mRNA Engineering Replete / Modified Grafts UNMODIFIED DONOR STEM CELLS ENGINEERED STEM CELLS • T - cells / Other Immune Cells Required for Robust Engraftm
Slide 13: Proof of Concept: JSP-Engineered HSCs Will Outcompete Normal HSCs
© 2021 Jasper Therapeutics, Inc. Proof of Concept: JSP - 502 Engineered HSCs Will Outcompete Normal HSCs And Can Be Given Together With JSP191 Conditioning 13 0.00 0.05 0.10 0.15 1000 10 0.1 100 1 SCF Concentration (ng/mL) Proliferation (OD 595) JSP - 502 CD117 (WT) Control 0.00 0.05 0.10 0.15 1000
Slide 14: JSP191 and eHSCs Significantly Expand the Eligible Patient Population
© 2021 Jasper Therapeutics, Inc. Allo - HCT for Heme Malignancies Allo - HCT for Non - Malignant Disease Autologous Gene Therapy JSP191 and eHSCs Significantly Expand the Eligible Patient Population for Curative Stem Cell Transplants 14 Severe / Refractory Autoimmune JSP191: ~$2B MARKET TRANSPLANTS
Slide 15: Jasper Expected Milestones
© 2021 Jasper Therapeutics, Inc. Jasper Expected Milestones • Q2 2021 – JSP191 AML/MDS Phase 1a top line 90 - day data • Q2 2021 – JSP191 AML/MDS open enrollment of Phase 1b expansion • Q4 2021 – JSP191 Autoimmune IND filing for Phase 1a pilot study • Q4 2021 – Engineered Stem Cell Platform in - viv
Slide 16: Jasper and Amplitude Add Significant Capital to Advance a Leader in Hematopoietic Stem Cell Transplant
© 2021 Jasper Therapeutics, Inc. Jasper and Amplitude Add Significant Capital to Advance a Formidable Leader in Hematopoietic Stem Cell Transplant for a Range of Indications Creating well funded leader in hematopoietic stem cells for a range of indications Pro forma valuation Share price $10.00 Pro-
Slide 17: Risk Factors
© 2021 Jasper Therapeutics, Inc. Risk Factors 17 The list below of risk factors has been prepared solely for purposes of the proposed private placement transaction (the “Priv ate Placement”) as part of the proposed business combination (the “Business Combination”) of Amplitude Healthcare Acquisition
Slide 18: Risk Factors (cont'd): Regulatory Regime for Product Candidates
© 2021 Jasper Therapeutics, Inc. Risk Factors (cont’d) 18 Risks Related to the Regulatory Regime for Jasper’s Product Candidates Jasper has no experience as a company in obtaining regulatory approval for a drug. The regulatory landscape that will govern Jasper’s product candidates is uncertain; regu
Slide 19: Risk Factors (cont'd): Intellectual Property
© 2021 Jasper Therapeutics, Inc. Risk Factors (cont’d) 19 Risks Related to Jasper’s Intellectual Property Jasper’s commercial success depends on its ability to obtain, maintain and protect its intellectual property and proprietary tec hnology. The patent protection Jasper obtains for its product can
Slide 20: Risk Factors (cont'd): Private Placement
© 2021 Jasper Therapeutics, Inc. Risk Factors (cont’d) 20 Risks Related to the Private Placement AMHC may be unable to raise sufficient capital in the Private Placement or otherwise obtain additional financing to complete the Business Combination or to fund the operations and growth of the combined